LRP12 and neoplasm: We identified LRP12 as a resistance biomarker in the PDX models and further validated the methylation differences of responders and non-responders in an independent cohort with single-locus methylation analyses in 35 additional formalin-fixed and paraffin-embedded (FFPE) primary tumor samples.